Advancing Genetic Therapeutics for Neurological Disease
Our mission is to translate cutting-edge neuroscience into transformative medicines and medical devices that address the root causes of debilitating neurological conditions.
Our Pipeline
Targeting the most pressing unmet needs in neurological disease through therapeutics and medical devices.
ALS
Multiple allele-selective programs targeting the genetic and sporadic drivers of ALS, designed for IND-enabling execution at $250K leveraging our computational design engine.
Alzheimer's Disease
A novel small-molecule approach targeting tau aggregation and neuroinflammatory pathways to slow cognitive decline.
Parkinson's Disease
Targeting alpha-synuclein misfolding with a first-in-class compound demonstrating neuroprotective activity in preclinical models.
Rare Neurological Disorders
Orphan disease program addressing rare monogenic neurological conditions with high unmet medical need.
Mechanism-First Drug Discovery
We start with deep biological insight, understanding the precise molecular mechanisms that drive neurodegeneration before designing therapeutics.
- Target validation grounded in human genetics and disease biology
- Proprietary screening platforms optimized for CNS drug discovery
- Integrated computational and experimental chemistry
- Translational biomarker strategy from day one
Partner With Baja Bio
We are actively seeking scientific collaborators, strategic partners, and investors who share our commitment to transforming the treatment of neurological disease.